Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FQSX1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,598
Award facts
- Contract value 100% obligated
- $20,598.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $20,598.16 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The award, issued on January 13, 2026, with an ultimate completion date of February 4, 2026, utilizes a firm fixed-price contract structure with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition vehicle designed to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
As a prime vendor contractor under the PPV-G GEN V program, DMS Pharmaceutical Group supplies an extensive portfolio of branded and generic pharmaceuticals, biologics, specialty medications, and medical consumables to support military healthcare operations globally. The company's underlying indefinite delivery contract, awarded in November 2025 with a ceiling value of $499,999,999 and extending through December 31, 2036, positions it as a critical supplier within the federal pharmaceutical supply chain. This particular delivery order for Stelara, an immunosuppressant biologic, represents routine execution of the company's obligations to provide specialized pharmaceutical products as needed by DoD medical facilities.
Quick answers
Who was awarded contract SPE2DR26FQSX1?
SPE2DR26FQSX1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26FQSX1 worth?
The government has obligated $20,598 on SPE2DR26FQSX1.
Is contract SPE2DR26FQSX1 an order under another contract?
Yes. SPE2DR26FQSX1 is a delivery order under SPE2DR25D9214, an indefinite delivery contract.
Was contract SPE2DR26FQSX1 competed?
The extent of competition for SPE2DR26FQSX1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award